Sheet	1	of 1									
INFC	RMA	ATION DISCLOSURE	APPLN. NO.			ATTY, DKT, NO.					
		CITATION	10/518,302			3687-101					
		OIPE	APPLIC								
	(Lise se	everal sheets if necessary)	ZOP FILING	PETTI et al.		GROU					
	JAN 0 4 2016										
		\ <u>R</u> ****		1623							
		TANDOUSET	9/	U.S. PATENT DO	DCUMENTS						
EXAMINES INITIAL	R	DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	FILING	DATE OPRIATE	
	\Box										
	+										
	+										
	+										
	\top										
	\prod										
			FC	REIGN PATENT	DOCUMENTS				TOANG	LATION	
		DOCUMENT	DATE	0	DUNTRY		CLASS	SUBCLASS	YES	NO	
	_	DOCOMENT	DATE		50141141		CLASS	JOBOLAGO	120	110	
	+					_					
	+				-	-					
	_										
	+						-	-			
	+-										
		OTHER DOC	UMENTS	Including Author	r. Title. Pertiner	nt page	s. Date.	etc.)			
		Barrowcliffe et al. "Th	ne anticoag	ulant activity of he	parin: Measuren				mical st	ructure"	
		J. Pharmaceut. & Biomed. Anal. 7:217-226 (1989). Hemker et al. "Elements from in vitro studies that help understand the action of heparins" Thrombosis Res.									
		Hemker et al. "Eleme Suppl. 14:1-10 (1991		vitro studies that	help understand	the act	ion of he	parins" lihro	mbosis	Res.	
		Klein et al. "Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular control of the co									
	weight heparin: A comparison with anti-Xa concentrations" Anesth. Analg. 91:1091-1095 (2000).										
i		Lembo et al. "Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital typ of human papillomavirus" Antimicrob. Agents Chemother. 52:1374-1381 (Apr 2008).									
		Pinna et al. "Inhibition							atives of	f	
		Escherichia coli K5 polysaccharide" Antimicrob. Agents Chemother. 52:3078-3084 (Sep 2008).									
		Razi et al. "Structural and functional properties of heparin analogues obtained by chemical sulphation of Escherichia coli K5 capsular polysaccharide" Biochem. J., 309:465-479 (1995).									
		Vicenzi et al. "Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide									
		derivatives" AIDS 17									
		- 100									
Examine	r	// outo Dianel/			Date Considere	d I	01/31/20	10			
LAMITING		L /Layla Bland/	ant sitution in i		200 Daw line there	∽ h =itotion li	Unatio seels	rmance and not	considered	Include	

Examiner: Initial in reference considered, wherein or not classon is in consumance with which copy of this form with next communication to application.

Form PTO-F8-A820 (Also PTO-1448)